Bicara Therapeutics BCAX Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's common stock, shares authorized (in shares)?
- Bicara Therapeutics (BCAX) reported common stock, shares authorized (in shares) of $500M in Q1 2026.
- How has Bicara Therapeutics's common stock, shares authorized (in shares) changed year-over-year?
- Bicara Therapeutics's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $500M to $500M.
- What is the long-term trend for Bicara Therapeutics's common stock, shares authorized (in shares)?
- Over 2 years (2023 to 2025), Bicara Therapeutics's common stock, shares authorized (in shares) has grown at a 17.0% compound annual growth rate (CAGR), from $365M to $500M.